A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
Epistemonikos ID: 58c914fb103921a724d3022c95d09fca32c0f4c7
First added on: Oct 02, 2026